NYXTHRACIS

This brand name is authorized in Austria, Estonia, Croatia, Italy, Lithuania, Poland

Active ingredients

The drug NYXTHRACIS contains one active pharmaceutical ingredient (API):

1 Obiltoxaximab UNII 29Z5DNL48C - OBILTOXAXIMAB

Obiltoxaximab is a monoclonal antibody that binds the protective antigen (PA) of B. anthracis. Obiltoxaximab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and oedema factor, the enzymatic toxin components responsible for the pathogenic effects of anthrax toxin. Read about Obiltoxaximab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
NYXTHRACIS Concentrate for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BC04		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BC Antibacterial monoclonal antibodies
Discover more medicines within J06BC04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1833678
Country: IT	Agenzia del Farmaco	Identifier(s): 049226018
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091351